GPRC6A transcripts are upregulated in prostate cancer, and in prostate cell lines, with ligands to GPRC6A such as calcium and arginine showing a dose-dependent stimulation of ERK activity as well as chemotaxis and proliferation [263]. This evidence concerns the gene GPRC6A and prostate carcinoma.